We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
- Authors
Schuster, Eugene F.; Lopez-Knowles, Elena; Alataki, Anastasia; Zabaglo, Lila; Folkerd, Elizabeth; Evans, David; Sidhu, Kally; Cheang, Maggie Chon U.; Tovey, Holly; Salto-Tellez, Manuel; Maxwell, Perry; Robertson, John; Smith, Ian; Bliss, Judith M.; Dowsett, Mitch
- Abstract
Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale molecular analysis to identify features that impact on the response of ER + HER2- BC to AI. We compare the 15% of poorest responders (PRs, n = 177) as measured by proportional Ki67 changes after 2 weeks of neoadjuvant AI to good responders (GRs, n = 190) selected from the top 50% responders in the POETIC trial and matched for baseline Ki67 categories. In this work, low ESR1 levels are associated with poor response, high proliferation, high expression of growth factor pathways and non-luminal subtypes. PRs having high ESR1 expression have similar proportions of luminal subtypes to GRs but lower plasma estradiol levels, lower expression of estrogen response genes, higher levels of tumor infiltrating lymphocytes and immune markers, and more TP53 mutations. Aromatase inhibitors are an effective treatment for ER+ breast cancer, but response is variable. Here, the authors undertake molecular analyse of response from the POETIC trial and identify several factors associated with response.
- Subjects
AROMATASE inhibitors; BREAST cancer; TUMOR-infiltrating immune cells; BIOMARKERS; BREAST; ESTRADIOL
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-39613-z